Literature DB >> 22670135

CDKL5-Related Disorders: From Clinical Description to Molecular Genetics.

N Bahi-Buisson1, T Bienvenu.   

Abstract

Mutations in the cyclin-dependent kinase-like 5 gene (CDKL5) have been described in girls with Rett-like features and early-onset epileptic encephalopathy including infantile spasms. To date, with more than 80 reported cases, the phenotype of CDKL5-related encephalopathy is better defined. The main features consist of early-onset seizures starting before 5 months of age, severe mental retardation with absent speech and Rett-like features such as hand stereotypies and deceleration of head growth. On the other hand, neuro-vegetative signs and developmental regression are rare in CDKL5 mutation patients. The CDKL5 gene encodes a serine threonine kinase protein which is characterized by a catalytic domain and a long C-terminal extension involved in the regulation of the catalytic activity of CDKL5 and in the sub-nuclear localization of the protein. To our knowledge, more than 70 different point mutations have been described including missense mutations within the catalytic domain, nonsense mutations causing the premature termination of the protein distributed in the entire open reading frame, splice variants, and frameshift mutations. Additionally, CDKL5 mutations have recently been described in 7 males with a more severe epileptic encephalopathy and a worse outcome compared to female patients. Finally, about 23 male and female patients have been identified with gross rearrangements encompassing all or part of the CDKL5 gene, with a phenotype reminiscent of CDKL5-related encephalopathy combined with dysmorphic features. Even if recent data clearly indicate that CDKL5 plays an important role in brain function, the protein remains largely uncharacterized. Phenotype-genotype correlation is additionally hampered by the relatively small number of patients described.

Entities:  

Year:  2011        PMID: 22670135      PMCID: PMC3366705          DOI: 10.1159/000331333

Source DB:  PubMed          Journal:  Mol Syndromol        ISSN: 1661-8769


  55 in total

1.  Identification of a novel CDKL5 exon and pathogenic mutations in patients with severe mental retardation, early-onset seizures and Rett-like features.

Authors:  Nils Rademacher; Melanie Hambrock; Ute Fischer; Bettina Moser; Berten Ceulemans; Wolfgang Lieb; Rainer Boor; Irina Stefanova; Gabriele Gillessen-Kaesbach; Charlotte Runge; Georg Christoph Korenke; Stefanie Spranger; Franco Laccone; Andreas Tzschach; Vera M Kalscheuer
Journal:  Neurogenetics       Date:  2011-02-12       Impact factor: 2.660

Review 2.  Levetiracetam in pediatrics.

Authors:  Federico Vigevano
Journal:  J Child Neurol       Date:  2005-02       Impact factor: 1.987

3.  An isoform of the severe encephalopathy-related CDKL5 gene, including a novel exon with extremely high sequence conservation, is specifically expressed in brain.

Authors:  Yann Fichou; Juliette Nectoux; Nadia Bahi-Buisson; Jamel Chelly; Thierry Bienvenu
Journal:  J Hum Genet       Date:  2010-12-02       Impact factor: 3.172

4.  The clinical pattern of the Rett syndrome.

Authors:  F Hanefeld
Journal:  Brain Dev       Date:  1985       Impact factor: 1.961

5.  Characterization of two unusual RS1 gene deletions segregating in Danish retinoschisis families.

Authors:  L Huopaniemi; H Tyynismaa; A Rantala; T Rosenberg; T Alitalo
Journal:  Hum Mutat       Date:  2000-10       Impact factor: 4.878

6.  A novel p.Arg970X mutation in the last exon of the CDKL5 gene resulting in late-onset seizure disorder.

Authors:  Stavroula Psoni; Patrick J Willems; Emmanuel Kanavakis; Ariadne Mavrou; Helen Frissyra; Joanne Traeger-Synodinos; Christalena Sofokleous; Periklis Makrythanassis; Sophia Kitsiou-Tzeli
Journal:  Eur J Paediatr Neurol       Date:  2009-05-09       Impact factor: 3.140

7.  Rett variants: a suggested model for inclusion criteria.

Authors:  B A Hagberg; O H Skjeldal
Journal:  Pediatr Neurol       Date:  1994-07       Impact factor: 3.372

Review 8.  Mutational spectrum of CDKL5 in early-onset encephalopathies: a study of a large collection of French patients and review of the literature.

Authors:  C Nemos; L Lambert; F Giuliano; B Doray; A Roubertie; A Goldenberg; B Delobel; V Layet; M A N'guyen; A Saunier; F Verneau; P Jonveaux; C Philippe
Journal:  Clin Genet       Date:  2009-10       Impact factor: 4.438

9.  Novel mutations in the CDKL5 gene, predicted effects and associated phenotypes.

Authors:  S Russo; M Marchi; F Cogliati; M T Bonati; M Pintaudi; E Veneselli; V Saletti; M Balestrini; B Ben-Zeev; L Larizza
Journal:  Neurogenetics       Date:  2009-02-25       Impact factor: 2.660

10.  CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders.

Authors:  Clark Lin; Brunella Franco; Marsha Rich Rosner
Journal:  Hum Mol Genet       Date:  2005-12-05       Impact factor: 6.150

View more
  28 in total

1.  Neurodevelopmental and neurobehavioral characteristics in males and females with CDKL5 duplications.

Authors:  Przemyslaw Szafranski; Sailaja Golla; Weihong Jin; Ping Fang; Patricia Hixson; Reuben Matalon; Daniel Kinney; Hans-Georg Bock; William Craigen; Janice L Smith; Weimin Bi; Ankita Patel; Sau Wai Cheung; Carlos A Bacino; Paweł Stankiewicz
Journal:  Eur J Hum Genet       Date:  2014-10-15       Impact factor: 4.246

2.  Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice.

Authors:  I-Ting Judy Wang; Megan Allen; Darren Goffin; Xinjian Zhu; Andrew H Fairless; Edward S Brodkin; Steve J Siegel; Eric D Marsh; Julie A Blendy; Zhaolan Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-10       Impact factor: 11.205

3.  Caregiver's perception of epilepsy treatment, quality of life and comorbidities in an international cohort of CDKL5 patients.

Authors:  S Amin; A Majumdar; A A Mallick; J Patel; R Scatchard; C A Partridge; A Lux
Journal:  Hippokratia       Date:  2017 Jul-Sep       Impact factor: 0.471

4.  CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.

Authors:  Scott T Demarest; Heather E Olson; Angela Moss; Elia Pestana-Knight; Xiaoming Zhang; Sumit Parikh; Lindsay C Swanson; Katherine D Riley; Grace A Bazin; Katie Angione; Lisa-Marie Niestroj; Dennis Lal; Elizabeth Juarez-Colunga; Tim A Benke
Journal:  Epilepsia       Date:  2019-07-16       Impact factor: 5.864

5.  CDKL5 and ARX mutations in males with early-onset epilepsy.

Authors:  Ghayda M Mirzaa; Alex R Paciorkowski; Eric D Marsh; Elizabeth M Berry-Kravis; Livija Medne; Asem Alkhateeb; Art Grix; Elaine C Wirrell; Berkley R Powell; Katherine C Nickels; Barbara Burton; Andrea Paras; Katherine Kim; Wendy Chung; William B Dobyns; Soma Das
Journal:  Pediatr Neurol       Date:  2013-05       Impact factor: 3.372

6.  Novel mutations in cyclin-dependent kinase-like 5 (CDKL5) gene in Indian cases of Rett syndrome.

Authors:  Dhanjit Kumar Das; Bhakti Mehta; Shyla R Menon; Sarbani Raha; Vrajesh Udani
Journal:  Neuromolecular Med       Date:  2012-12-15       Impact factor: 3.843

7.  Mutations in the C-terminus of CDKL5: proceed with caution.

Authors:  Bertrand Diebold; Chloé Delépine; Svetlana Gataullina; Andrée Delahaye; Juliette Nectoux; Thierry Bienvenu
Journal:  Eur J Hum Genet       Date:  2013-06-12       Impact factor: 4.246

8.  Loss of CDKL5 in Glutamatergic Neurons Disrupts Hippocampal Microcircuitry and Leads to Memory Impairment in Mice.

Authors:  Sheng Tang; I-Ting Judy Wang; Cuiyong Yue; Hajime Takano; Barbara Terzic; Katarina Pance; Jun Y Lee; Yue Cui; Douglas A Coulter; Zhaolan Zhou
Journal:  J Neurosci       Date:  2017-07-03       Impact factor: 6.167

Review 9.  The challenges and innovations for therapy in children with epilepsy.

Authors:  Jo M Wilmshurst; Anne T Berg; Lieven Lagae; Charles R Newton; J Helen Cross
Journal:  Nat Rev Neurol       Date:  2014-04-08       Impact factor: 42.937

10.  Increased DNA Damage and Apoptosis in CDKL5-Deficient Neurons.

Authors:  Manuela Loi; Stefania Trazzi; Claudia Fuchs; Giuseppe Galvani; Giorgio Medici; Laura Gennaccaro; Marianna Tassinari; Elisabetta Ciani
Journal:  Mol Neurobiol       Date:  2020-01-30       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.